Avicanna Inc. (AVCN) Q4 2023 Earnings Call

Investor webinar replay

Replay transcript excerpt

which yielded 51% growth in our finished products sold in Canada. This expansion was increased through the number of commercial SKUs, through the number of commercial listings, and the fact that we have now launched products across seven different medical platforms, including our own MyMedic. Our R&D and clinical efforts Sustaining our intellectual property has also expanded and has led to two new strategic collaborations with two separate international pharmaceutical companies and has led to the marketing authorization of our first pharmaceutical product through Invima called Trunerex, which was recently announced during early Q1 2024. An overview of MyMedi. So on August 2nd, 2023, we proudly launched our new medical cannabis platform called MyMedi.ca. As mentioned, this was arrived from the acquisition of the Sharpless Drug Mart division. MyMedi.ca features a diverse portfolio of products from Avicana and 15 licensed producers here in Canada. The platform is available nationwide and led by our pharmacists, led bilingual patient support programs, in addition to educational resources for the medical community, all of which is to facilitate the incorporation of medical cannabis into the healthcare regimen. MyMedi is operated under Northern Green Canada, which is a licensed producer and logistics operator of the business unit. Through MyMedi.ca, the company provides what we believe to be the most robust medical cannabis access program and support program nationwide to tens of thousands of Canadian patients who have obtained medical cannabis authorizations from their healthcare providers. Other MyMedi.ca features include, as I mentioned, multi-brand from 15 different licensed producers with about 200 plus SKUs, including 40 different brands. The emphasis is really on of...